Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst Major insurers won't pay for Biogen's Alzheimer’s drug until they get more proof that it works: Bloomberg survey AstraZeneca, after years of delays and spiraling costs, opens Cambridge R&D site. Will the bet pay off? FDA, working to tackle pandemic inspection backlog, struggles with foreign oversight and site visits for new drugs Data manipulation expert Elisabeth Bik compares the tales of 2 accused biotechs: Cassava and Athira Medtronic's surgery robot rollout hits supply chain speed bumps White House unveils $1.5B investment to train more than 22,700 new healthcare providers Sanofi coughs up $180M to settle Pompe disease royalty payment dispute Rafael resets after phase 3 flop, parting ways with 5 execs and reinstating telecom tycoon as CEO Cardiologs scores pediatric heart AI diagnostic clearance from FDA ahead of Philips buyout Epic's sepsis algorithm may have caused alert fatigue with 43% alert increase during pandemic Featured Story | By Angus Liu The COVID-19 pandemic is creating a $100 billion pharma goliath. Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from its BioNTech-partnered COVID vaccine and antiviral drug Paxlovid, one analyst estimates. read more |
| |
|---|
|
Top Stories By Robert King A Bloomberg survey of 25 major insurers found that none of the payers believe it's medically necessary to cover a controversial Alzheimer's drug made by Biogen. read more By Nick Paul Taylor Five years late and 200% over budget, AstraZeneca has finally formally unveiled the Cambridge, U.K., site that is at the heart of its R&D strategy. read more By Fraiser Kansteiner More than a year and a half into the COVID-19 pandemic, the FDA has started to right the ship on the pace of its domestic drug manufacturing inspections. Still, the agency continues to struggle with oversight of foreign plants, and a growing number of new drug applications are facing delays, a report shows. read more By Annalee Armstrong Fierce Biotech caught up with one of the scientists who spotted irregularities in Cassava’s research after the issue was flagged in a citizens petition to the FDA. read more By Conor Hale On a quarterly earnings call with investors, Martha described the launch as currently holding in a “limited-release phase.” read more By Dave Muoio American Rescue Plan-funded investments will yield "the largest field strength in history" for the National Health Service Corps, Nurse Corps and the Substance Use Disorder Treatment and Recovery Program, according to the White House. read more By Angus Liu As Sanofi's Pompe disease franchise fuels its growth in rare diseases, the company has inked a $180 million settlement related to a license for a key medicine. read more By Nick Paul Taylor Rafael Holdings is clearing out its C-suite. Weeks after the failure of its lead cancer drug, Rafael has disclosed the planned departures of five executives as it adapts to life without a near-approval asset. read more By Conor Hale Philips’ latest M&A target, French artificial intelligence developer Cardiologs, received a new FDA clearance that expands the use of its cardiac diagnostic platform into pediatrics. It will be used to identify potential irregular heartbeats among electrocardiogram recordings. read more By Rebecca Torrence A new JAMA Network Open study found that Epic's sepsis warning system may have burdened providers during the pandemic with a deluge of alerts, with the number of alerts increasing 43% in the three weeks after the hospitals' first cases of COVID-19 even as total patient volumes decreased. read more |
| Webinar: Give Your Medtech Sales a Collaboration Advantage Tuesday, November 30 | 12pm ET / 9am PT Medtech companies have long been burdened by inefficient communication between front office (sales) and back office (operations). It’s clear a new approach is needed – one that increases collaboration and communication between sales and operations, improves the customer experience, and increases revenue. Learn More. |
|
